Press release
Oramed Appoints Yadin Rozov to its Board of Directors
NEW YORK, April 4, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"NEW YORK, April 4, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Yadin Rozov to its Board of Directors effective April 1, 2022. The Board determined that Mr. Rozov qualifies as an independent director under the listing rules of the Nasdaq Capital Market. \nMr. Rozov is an investment professional with over twenty years of experience in capital markets, corporate finance, investment banking, and investment management with substantial experience in corporate strategy and governance. He is the founder and Managing Partner of Terrace Edge Ventures LLC, a financial advisory firm. Previously, Mr. Rozov was a Partner of GoldenTree Asset Management LLC, a leading global credit asset management firm, where he also served as the Chief Executive Officer and President of Syncora Guarantee Inc. and Chief Executive Officer of Financial Guaranty UK Ltd, each of which are stand-alone specialty insurance companies owned by GoldenTree. Additionally, he was a Partner and Managing Director at Moelis & Company where he headed the Financial Institution Advisory group. While at Moelis, Mr. Rozov helped co-found College Avenue Student Loans LLC and served on its board and co-founded Chamonix Partners Capital Management LLC. Before Moelis, Mr. Rozov was a Managing Director at UBS AG, where he was the Head of the Americas for the Repositioning Group. \nMr. Rozov earned an M.Sc. in data science from Columbia University and a bachelor's degree with highest honors in physics and materials engineering from Rutgers University.\n\"We welcome Yadin as a new independent director. His deep experience in corporate finance will be an asset to Oramed as we advance toward becoming a commercial stage company following our pivotal Phase 3 studies for the world's first oral insulin capsule,\" said Oramed Chief Executive Officer, Nadav Kidron. \nAbout Oramed Pharmaceuticals \nOramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of ...